Skip to main content
. 2021 Jun 23;11:634841. doi: 10.3389/fonc.2021.634841

Figure 6.

Figure 6

Relative expression of miRNAs in COAD patients. (A) The relative expression level of hsa-miR-296-5p in COAD. (B) The relative expression level of hsa-miR-155-5p in COAD. (C) The relative expression level of hsa-miR-6761-5p in COAD. (D) The relative expression level of hsa-miR-582-5p in COAD. (E) The relative expression level of hsa-miR-452-3p in COAD. (F) The relative expression level of hsa-miR-330-5p in COAD. (G) The relative expression level of hsa-miR-3127-5p in COAD. (H) The relative expression level of hsa-miR-146b-5p in COAD. (I) The relative expression level of hsa-miR-99a-5p in COAD. (J) The relative expression level of hsa-miR-874-3p in COAD. (K) The relative expression level of hsa-miR-132-3p in COAD. (L) The relative expression level of hsa-miR-625-3p in COAD. (M) The relative expression level of hsa-miR-552-5p in COAD. (N) The relative expression level of hsa-miR-195-3p in COAD. (O) The relative expression level of hsa-miR-452-5p in COAD. (P) The relative expression level of hsa-miR-224-5p in COAD. (Q) The relative expression level of hsa-miR-582-3p in COAD. (R) The relative expression level of and hsa-miR-592 in COAD. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.